Montreal, November 14, 2016 – The innovation in medical technology sector in Quebec is the main objective of the partnership between Desjardins – Innovatech and the Health Technology Campus (CTS). It is within this framework that $ 250,000 has recently been invested by Desjardins – Innovatech, through the CTS, in the EMcision firm, which is innovating in the fight against cancer.

“Our products provide clinicians a non-invasive access to deep organs in the digestive system for the first time,” said François Poulin, CEO of EMcision International. With the help of the CTS, we are more effectively pursuing our goal of improving the therapeutic arsenal against the terrible cancers of the biliary ducts and the pancreas “.

“The CTS is proud to add EMcision to its group of companies,” added Guillaume Hervé, Chairman of CTS. The company combines business and scientific expertise to develop and promote medical devices that are clinically relevant, cost-effective and improve the quality of life of cancer patients. ”

In 2002, EMcision innovated with Habib 4X, which treats liver cancer and ranks first on hepatic resection devices in the United States. The success of the device has created new devices to improve health care in distinct areas:

  • Gastroenterology: Habib Endoblate, Habib EndoHPB, Habib EUS RFA;
  • Radiology: Habib Percutaneous HPB, Habib VesOpen, Habib VesCoag.

 

In addition, Habib EndoHPB and Habib EUS RFA have been adapted to improve the treatment of cholangiocarcinoma and pancreatic cancer. In addition, EMcision devices are compatible with the radio frequency generators most commonly used by gastroenterologists. They are also single-use and serve as additions to common palliative treatments to prolong the survival time of patients which is the main objective of EMCision.

Thus, the company can advance surgical and medical techniques by harnessing the power and precision of radiofrequency energy for specific applications in percutaneous and open procedures, laparoscopic, vascular and endoscopic surgeries.

Desjardins – Innovatech, through the CTS, allows the company to reach a milestone thanks to the $ 250,000 invested. With the number of specialized catheters distributed globally increasing by 9,500 per year, 83% growth in sales in the United States in the last 12 months and 25 countries where products are distributed, the company has ambition to continue to develop at a sustained pace.

 

About EMcision

EMcision is a medical device company with offices in Montreal and London that develops and markets a range of probes for the removal of biological tissues. The company is particularly distinguished by its innovative designs, which allows them to reach anatomical regions traditionally out of reach. EMcision aims to maximize the therapeutic effects of high-frequency electrical energy to improve the effectiveness of treatments against several cancers, particularly in the pancreas and bile ducts.

 About CTS

CTS is an accelerator of companies in the field of medical technologies which offers them to develop faster and increases their chances of success. The goal of the CTS is to offer start-up companies a unique proposition with structured framework that allows them to focus on developing their technology, reaching market dynamics and gaining the visibility they need to start and develop internationally.

About Desjardins – Innovatech

Created in 2005, the Desjardins – Innovatech fund was created by the initiative of the Government of Québec and Capital régional et coopératif Desjardins. With more than $ 55 million invested in nearly 40 companies and funds, Desjardins – Innovatech’s main mission is to promote and support companies from Quebec, who involved in the development of technological innovation or Industrialists and the new generation of Quebec innovation entrepreneurs, with their capital financing. In order to fulfill its mission, the fund joins forces with other players in the technological field – specialized investment funds, entrepreneurs, financial angels, technological company’s accelerators – contributing to increase PME in terms of job creation and economic development.

For additional information (journalists only)

EMcision

François Poulin

President

514 994-9649

Francois.poulin@emcision.com

CTS

Romain Lortille Bruel

Director of Business Development

514-274-1001 or 514-808-9775

Lortillebruel@ctssante.ca

Desjardins – Innovatech

Richard Lacasse

Media spokesperson

418-835-8444 or 1-866-835-8444, ext. 556 3163

Media@desjardins.com

Menu